Stockpolly
Search
AVR · NASDAQ · Medical - Devices

Anteris Technologies (AVR)

Develops the investigational DurAVR valve system built on ADAPT tissue.

$8.51
Pre-market−0.09 (−1.05%)
At close$8.60(+1.78%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue111111110001
Cost of revenue100000000110
Gross profit000000000001
111618192221222123292432
Research & development81012131413161617201723
050600000978
General & administrative000000000008
Other expenses427088656000
Operating income−11−16−18−19−22−21−22−21−22−29−24−31
112002000022
Interest income000000000000
Interest expense000000000000
Other non-operating income0−1−20−100000−2−2
Income before tax−11−15−16−19−22−19−22−21−22−29−22−29
Income tax expense000000000000
Net income from continuing operations−11−15−16−19−22−19−22−21−22−29−23−29
Other adjustments0000—0000000
Net income−11−14−16−19−22−19−22−21−22−29−23−29
EPS, basic−$0.30−$0.39−$0.45−$0.52−$0.61−$0.82−$0.93−$0.89−$0.94−$1.24−$0.28−$0.30
EPS, diluted−$0.30−$0.39−$0.45−$0.52−$0.61−$0.82−$0.93−$0.89−$0.94−$1.24−$0.28−$0.30
Weighted average shares, basic363636363624242424248397
Weighted average shares, diluted363636363624242424248397
EBITDA−11−15−16−18−20−21−22−21−22−29−22−28
Depreciation & amortization000000000000
EBIT−12−15−16−19−21−22−22−21−22−29−22−29